A student who was caught on CCTV trying to sexually assault a woman at an east London bus stop has been jailed for four years.

[caption id="" align="alignnone" width="324"] From ‘The Red Tree’ by Shaun Tan[/caption] Have you ever played Hearts? It’s a card game. For our purposes, the important part is this: every card in the heart suit is worth points, and (just like golf) players want to avoid those points. I played a lot of Hearts as a [...]

"I am very aware that I'm not the only one going through this torture" Read our live coronavirus updates HERE

Draper is one of the thousands of people in the UK to have been diagnosed with coronavirus

"Where there is life, there is hope," Garraway wrote in her emotional post

Coronavirus: the symptoms

Garraway's husband remains in hospital with coronavirus

Draper has been in hospital with Covid-19 since late March

Zerhouni is thought to be the favorite, said two people, and one person said that Azar personally prefers Zerhouni for the role.

A jury hears how a woman who was allegedly gang raped by prominent Chinese actor Yunxiang Gao, and a producer, in a Sydney hotel room begged the men to let her go.

AN EXOTIC dancer claims she was abused and “drugged into near unconsciousness” for not going along with a club’s scheme. WARNING: Graphic.

North Melbourne footballer Majak Daw has been committed to stand trial over the alleged rape of a teenage girl in 2007.

Lyra Therapeutics, a biotech company developing a new way to treat your persistently runny nose, has raised $56 million in its public markets debut. Late Thursday, Lyra offered 3.5 million shares priced at $16 apiece, which was the high end of its projected $14 to $16 price range. Those shares are expected to begin trading […]

PTC Therapeutics has reached an agreement to acquire Censa Pharmaceuticals and its lead asset, an experimental metabolic disorder therapy that is now being prepared for a pivotal study. The deal, announced after the market close Wednesday, will bring South Plainfield, NJ-based PTC (NASDAQ: PTCT) another compound for its pipeline of rare disease drugs. Wellesley, MA-based […]

Massachusetts-based biotech Disarm Therapeutics has hired Dr Alvin Shih as their new President and CEO.

The Cambridge, Mass.-based firm has set itself the task of creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central drive of neurological disease.

Dr Shih brings to the role a range of experiences. Having graduated with a biology degree from Vanderbilt University in 1996, Shih joined management consultancy McKinsey where he worked as a business analyst for two years.

read more

Dr Lisa von Moltke has left Aklermes and has joined Seres Therapeutics as its new Chief Medical Officer.

Chief Executive Officer at Seres, Eric Shaff, said Seres will benefit from von Moltke’s “extensive experience directing successful development programs, leading clinical teams, and interacting with regulatory agencies across multiple areas of medicine.”

read more

The pharmaceutical firm has purchased the company, which specializes in advancing treatments and diagnostics for ocular disorders.

This week, I’m rerunning some popular posts while I prepare for this Friday’s video webinar: Industry Update and COVID-19 Impact: PBMs & Payers.

I suspect this deal will remain profitable for the participating companies even as COVID-19 alters the US. prescription payer mix. Click here to see the original post and comments from January 2020. National market shares for the largest PBMs in 2019 appears as Exhibit 88 of our 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers.

P.S. Sorry that today's meme is one day too late for Star Wars day.

---

Just before the holidays, Cigna’s Express Scripts business announced a market-changing deal with Prime Therapeutics. Click here to read the press release.

There's been very little written about this transaction, though it has potentially major implications. Below, I share my thoughts on the following topics arising from the deal:

• Implications for manufacturers and pharmacies

• The role of the secretive Ascent Health Services

• What this all means for Walgreens

• Why the Federal Trade Commission won’t challenge the deal

A few weeks ago, I explained why integrated insurer / PBM / specialty pharmacy / provider organizations are poised to restructure U.S. drug channels. The Express Scripts / Prime deal signals that the channel will continue its amazing pace of reinvention.

The scale, scope, and interconnectedness of today’s market participants make the system increasingly resistant to massive disruption from either external players like Amazon or a government takeover. Like it or not, the channel will continue to gain power and extract profit. Read on and see if you agree.
Read more »

In another strategic M&A deal announced so far this month, PTC Therapeutics has entered into an agreement…

Hosam Maher Husein Smadi, 19, has been arrested and charged in a federal criminal complaint with attempting to use a weapon of mass destruction.

Hosam Maher Husein Smadi pleaded guilty today before U.S. District Judge Barbara M. G. Lynn to a felony offense related to his attempted bombing of a downtown Dallas skyscraper in September 2009.

Hosam Maher Husein Smadi was sentenced today by U.S. District Court Judge Barbara M. G. Lynn to 24 years in prison for his attempted bombing of a downtown Dallas skyscraper in September 2009.

The Justice Department today released a proposed rule that aims to prevent and respond to sexual abuse in incarceration settings, in accordance with the Prison Rape Elimination Act.

Attorney General Eric Holder today announced revisions to the Uniform Crime Report’s (UCR) definition of rape, which will lead to a more comprehensive statistical reporting of rape nationwide. The new definition is more inclusive, better reflects state criminal codes and focuses on the various forms of sexual penetration understood to be rape.

The Justice Department today released a final rule to prevent, detect and respond to sexual abuse in confinement facilities, in accordance with the Prison Rape Elimination Act of 2003 (PREA).

Attorney General Eric Holder today announced a revised version of the National Protocol for Sexual Assault Medical Forensic Examinations (SAFE Protocol, 2d.) The SAFE Protocol is a voluntary best practices guide to conducting sexual assault medical forensic examinations protocols.

Deputy Attorney General James M. Cole and Principal Deputy Assistant Attorney General for Justice Programs Mary Lou Leary announced today that the vast majority of U.S. states and territories have informed the Department of Justice that they intend to take steps to reduce sexual assaults in prisons, in accordance with federal law.

"These [PREA] standards, like the law mandating them, are intended to address a serious public safety, public health and human rights problem – the incidence of sexual violence in our nation’s confinement facilities."

"It’s clear that our nation will no longer tolerate sexual violence in our prisons, jails and juvenile detention centers – and that’s something we should all be proud of."

Axsome Therapeutics Inc.'s (AXSM) phase II/III trial of investigational drug AXS-05 in Alzheimer's disease agitation has met the primary endpoint.

Shares of Relmada Therapeutics Inc. (RLMD) have gained 19 percent so far this year and trade around $37.

Neuroscience has had a tough run of news lately. With Amgen deprioritizing neuro this year, Pfizer doing the same last year, and others like BMS, GSK, and AZ cutting back on CNS a few years earlier, it would seem dark

The post The Promise Of Precision Neuroscience And Launch Of Arkuda Therapeutics appeared first on LifeSciVC.

Today Alkermes announced its acquisition of Rodin Therapeutics, a leader in the field of synaptic dysfunction and neuronal epigenetics. Alkermes extensive experience in CNS diseases made them an ideal partner for Rodin, and this acquisition helps expand Alkermes’ efforts into

The post Thinking Boldly: Alkermes Acquires Rodin Therapeutics appeared first on LifeSciVC.

PTC Therapeutics is adding to its rare disease pipeline with a midstage biotech buyout with a low upfront payment tied in with stock and biobucks.

Just a few months after Alexion snapped up complement inhibitor biotech Achillion, Gemini Therapeutics has nabbed one of its key R&D execs as its new chief medical officer.

Tough times at Orchard Therapeutics as it swings the ax across staffers and facilities, phases in new pipeline advances and reduces interest in others.

siRNNs could enable RNAi knockdown of therapeutic targets in a broader range of cells and tissue types than siRNA.

Fusing therapeutic proteins to affibodies with pH-dependent binding to neonatal Fc receptor could improve the proteins' half-lives.

When Jerry wrote about Vincent Callebaut's proposed vertical farm for New York City, he called it a Locavore Wet Dream; I called it one of the silliest, most overwrought jump-the-shark vertical farm ideas ever